Unknown

Dataset Information

0

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.


ABSTRACT: AIMS:To assess the pharmacokinetics/pharmacodynamics (PK/PD) of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor that increases urinary glucose excretion (UGE) and its major metabolite, dapagliflozin-3-O-glucuronide (D3OG), in Japanese patients with type 1 diabetes (T1D) and inadequate glycaemic control (HbA1c 7%-10%). MATERIALS AND METHODS:Japanese patients (18-65?years) with inadequately controlled T1D were randomized 1:1:1 to dapagliflozin 5 mg, 10 mg or placebo (n?=?14 each) once daily for 7 days, with adjustable insulin. The PK/PD characteristics of dapagliflozin and D3OG were assessed on Day 7. Patients underwent follow-up evaluation on Days 8 and 14. Adverse events (AEs), hypoglycaemic episodes and events of diabetic ketoacidosis (DKA) were recorded over the treatment and follow-up periods. RESULTS:A total of 42 randomized patients received dapagliflozin or placebo. PK variables increased in a dose-dependent manner. D3OG was generated rapidly, with a median time to maximum plasma concentration of 2.0 hours (1.0-3.0). The dapagliflozin dose-UGE relationship was attenuated, with larger insulin dose reductions than anticipated. Mean percent (standard error) changes in total daily insulin dose from baseline to Day 7 were?-?36.86% (3.32), -39.13% (2.68) and?-?4.97% (5.28) for dapagliflozin 5 mg and 10 mg and for placebo, respectively. No DKA was reported. AEs were consistent with the established dapagliflozin safety profile. There was no increase in hypoglycaemia. CONCLUSIONS:The PK and safety profiles of dapagliflozin in Japanese patients with T1D were consistent with previous studies, but with an unanticipated attenuation of the PD dose-response measured as UGE.

SUBMITTER: Watada H 

PROVIDER: S-EPMC6590304 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.

Watada Hirotaka H   Shiramoto Masanari M   Ueda Shinya S   Tang Weifeng W   Asano Michiko M   Thorén Fredrik F   Kim Hyosung H   Yajima Toshitaka T   Boulton David W DW   Araki Eiichi E  

Diabetes, obesity & metabolism 20181221 4


<h4>Aims</h4>To assess the pharmacokinetics/pharmacodynamics (PK/PD) of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor that increases urinary glucose excretion (UGE) and its major metabolite, dapagliflozin-3-O-glucuronide (D3OG), in Japanese patients with type 1 diabetes (T1D) and inadequate glycaemic control (HbA1c 7%-10%).<h4>Materials and methods</h4>Japanese patients (18-65 years) with inadequately controlled T1D were randomized 1:1:1 to dapagliflozin 5 mg, 10 mg or placebo (n =   ...[more]

Similar Datasets

| S-EPMC3687097 | biostudies-literature
| S-EPMC4569680 | biostudies-literature
| S-EPMC4269643 | biostudies-literature
| S-EPMC4020257 | biostudies-literature
| S-EPMC4415995 | biostudies-literature
| S-EPMC9519412 | biostudies-literature
| S-EPMC5680437 | biostudies-literature
| S-EPMC4486092 | biostudies-literature
| S-EPMC6220780 | biostudies-literature
| S-EPMC8844171 | biostudies-literature